Accumulating evidence suggests that USP7 plays crucial roles in cancers, and many advances have been achieved regarding USP7 as a novel therapeutic target for cancer.36–38 Of note, targeting USP7-mediated DNMT1 stabilisation in pancreatic cancer holds distinct promise as therapeutic application.39 Therefore, blockade of the WDR1–USP7–β-Catenin axis could be a therapeutic strategy for PDAC treatment. Here, DNMT1 is linked to familial pancreatic carcinoma.